KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Assets: 2011-2025

Historic Non-Current Assets for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $825.9 million.

  • Supernus Pharmaceuticals' Non-Current Assets rose 17.53% to $825.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $825.9 million, marking a year-over-year increase of 17.53%. This contributed to the annual value of $682.0 million for FY2024, which is 13.07% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Non-Current Assets of $825.9 million as of Q3 2025, which was up 28.33% from $643.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Non-Current Assets high stood at $1.1 billion for Q4 2021, and its period low was $643.5 million during Q2 2025.
  • Its 3-year average for Non-Current Assets is $763.3 million, with a median of $759.8 million in 2024.
  • In the last 5 years, Supernus Pharmaceuticals' Non-Current Assets soared by 45.61% in 2021 and then decreased by 18.98% in 2023.
  • Supernus Pharmaceuticals' Non-Current Assets (Quarterly) stood at $1.1 billion in 2021, then fell by 10.96% to $968.4 million in 2022, then declined by 18.98% to $784.6 million in 2023, then fell by 13.07% to $682.0 million in 2024, then rose by 17.53% to $825.9 million in 2025.
  • Its Non-Current Assets stands at $825.9 million for Q3 2025, versus $643.5 million for Q2 2025 and $659.7 million for Q1 2025.